Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRL1 | P41146 | 19/20 | 0.48 |
| ▸ | OPRM1 | P35372 | 18/20 | 0.48 |
| ▸ | OPRK1 | P41145 | 14/20 | 0.48 |
| ▸ | OPRD1 | P41143 | 5/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2247469 | 1.00 | OPRL1 (0.48) | OPRL1OPRM1OPRK1OPRD1KDM4E | |
| SCHEMBL3582920 | 0.83 | KDM4E (0.41) | OPRL1OPRM1OPRK1OPRD1KDM4E | |
| SCHEMBL3582923 | 0.83 | KDM4E (0.41) | OPRL1OPRM1OPRK1OPRD1KDM4E | |
| SCHEMBL3582606 | 0.81 | CHRNA7 (0.52) | OPRL1OPRM1OPRK1OPRD1KDM4E | |
| SCHEMBL3582603 | 0.81 | CHRNA7 (0.52) | OPRL1OPRM1OPRK1OPRD1KDM4E | |
| SCHEMBL12931778 | 0.78 | OPRL1 (0.46) | OPRL1OPRM1OPRK1OPRD1 | |
| SCHEMBL9984580 | 0.77 | OPRL1 (0.56) | OPRL1OPRM1OPRK1OPRD1 | |
| SCHEMBL13177689 | 0.76 | OPRL1 (0.54) | OPRL1OPRM1OPRK1OPRD1 | |
| SCHEMBL3587101 | 0.74 | KDM4E (0.47) | OPRL1OPRM1OPRK1OPRD1KDM4E | |
| SCHEMBL3587098 | 0.74 | KDM4E (0.47) | OPRL1OPRM1OPRK1OPRD1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2280008-B1 | HETEROCYCLIC-SUBSTITUTED PIPERIDINES AS ORL-1 LIGANDS | PURDUE PHARMA LP (US) | 2013-05-29 | — | — | EP | disclosed |
| EP-1491212-B1 | REMEDY FOR SLEEP DISTURBANCE | MITSUBISHI TANABE PHARMA CORP (JP) | 2012-08-08 | — | — | EP | disclosed |
| EP-2394997-A1 | PROCESS FOR PREPARING 1-(4-PIPERIDINYL)BENZIMIDAZOLONE DERIVATIVES | Mitsubishi Tanabe Pharma Corporation (JP) | 2011-12-14 | — | — | EP | disclosed |
| US-8003669-B2 | Remedy for sleep disturbance | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-08-23 | — | — | US | disclosed |
| US-8003669-B2 | Remedy for sleep disturbance | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-08-23 | — | — | US | disclosed |
| US-20090253747-A1 | Remedy for sleep disturbance | TESHIMA KOJI | 2009-10-08 | — | — | US | disclosed |
| US-20090253747-A1 | Remedy for sleep disturbance | TESHIMA KOJI | 2009-10-08 | — | — | US | disclosed |
| US-7566728-B2 | Advance circadian rhythm disorders; using opioid receptor antagonist | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-07-28 | — | — | US | disclosed |
| US-7566728-B2 | Advance circadian rhythm disorders; using opioid receptor antagonist | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-07-28 | — | — | US | disclosed |
| US-20050119308-A1 | Remedy for sleep disturbance | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2005-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050119308-A1 | Remedy for sleep disturbance | PER2, HCRTR1, HCRTR2 | OPRL1 10/4885OPRM1 115/4885OPRK1 63/4885 |
| US-20090253747-A1 | Remedy for sleep disturbance | PER2, HCRTR1, HCRTR2 | OPRL1 10/4885OPRM1 115/4885OPRK1 63/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.